OSOD has conducted over 2000+ studies with 7+ approvals both published and non-disclosed, in our 30-year history spanning the development process from initial iterative investigative studies, to chronic GLP-compliant safety studies, to advising on clinical testing strategy.
The eye is often at the forefront of innovative therapies and we have been involved with many. Our skilled ophthalmologists and technicians have the ability to administer therapies and evaluate their safety in all laboratory animal species from rodents, to minipigs, to nonhuman primates.
As a primary preclinical partner for the development of approved ophthalmic therapies and clinical testing approval for many others, we know our approach works.
- Lucentis - 2006 O'Neill, C.A., et.al., 2003. 26-week intravitreal injection toxicity study with rhuFab VEGF in cynomolgus monkeys with an 8-week recovery. Investigative Ophthalmology & Visual Science, 44(13).
- Eylea - 2011 Zimmer, E., et.al., 2006. Safety evaluation of intravitreal administration of VEGF trap in cynomolgus monkeys for 13 weeks. Investigative Ophthalmology & Visual Science, 47(13).
- Xiidra - 2016 Murphy, C. J., et.al., 2011. The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs. Investigative ophthalmology & visual science, 52(6).
- Susvimo - 2020 Bantseev, V., et.al., 2020. Evaluation of surgical factors affecting vitreous hemorrhage following port delivery system with ranibizumab implant insertion in a minipig model. Retina (Philadelphia, Pa.), 40(8).
- Durysta - 2021 Shen, J., et.al., 2020. Nonclinical pharmacokinetic and pharmacodynamic assessment of bimatoprost following a single intracameral injection of sustained-release implants. Translational Vision Science & Technology, 9(4).